{
  "trade_id": "TRD-20260107-FBIO-PDUFA",
  "ticker": "FBIO",
  "archetype": "pdufa",
  "status": "active",
  "thesis": {
    "summary": "PDUFA approval for CUTX-101 (Menkes Disease). Resubmission accepted Dec 15, 2025 following CMC-only CRL in Sep 2025. Efficacy/Safety not in question.",
    "catalyst": "FDA Decision (PDUFA)",
    "catalyst_date": "2026-01-14",
    "linked_event": "EVT-2026-034"
  },
  "scoring": {
    "catalyst": 2.0,
    "mispricing": 1.5,
    "noise_survival": 1.5,
    "downside_floor": 1.5,
    "risk_reward": 2.0,
    "info_half_life": 0.5,
    "base_score": 9.0,
    "adjustments": [],
    "final_score": 9.0
  },
  "decision": {
    "action": "BUY",
    "date": "2026-01-07",
    "rationale": "Score 9.0 > 8.25. High conviction setup due to 'CMC-only' CRL history and strong efficacy data in rare pediatric disease."
  },
  "position": {
    "entry_date": "2026-01-07",
    "entry_price": 4.27,
    "shares": 87,
    "cost_basis": 371.49,
    "size_percent": 0.0148,
    "stop_price": null,
    "target_price": 8.00,
    "order_id": "mock-fbio-1",
    "ibkr_account": "paper"
  },
  "exit_plan": {
    "info_parity_weights": {
      "media": 0.5,
      "iv": 1.5,
      "price": 1.0
    },
    "thesis_break_triggers": [
      "CRL received",
      "Major Amendment delay (>3 months)",
      "AdCom announced unexpectedly"
    ]
  },
  "monitoring": [
    {
      "date": "2026-01-07",
      "price": 4.27,
      "action": "OPEN",
      "notes": "Opened position. PDUFA in 7 days."
    }
  ],
  "precedents": [
    "Protalix (PLX) - CRL for CMC, Approved",
    "Vericel (VCEL) - Manufacturing remediation"
  ],
  "tags": ["pdufa", "rare_disease", "resubmission", "biotech"]
}
